earnings
confidence high
sentiment positive
materiality 0.65
Precigen Q1 revenue $32M (+31% YoY); Fast Track for PRGN-3006 in AML
PRECIGEN, INC.
2022-Q1 EPS reported
-$0.10
revenue$32,021,000
- Total revenues $32.0M, up 31% vs $24.5M YoY; net loss $19.3M ($0.10/share).
- Cash, equivalents, short- & long-term investments $142.1M as of March 31, 2022.
- FDA Fast Track designation for PRGN-3006 UltraCAR-T in relapsed/refractory AML.
- Phase 2 study for PRGN-2012 in RRP dosed first patient; Phase 1b expansion arm for PRGN-3006 initiated.
- R&D expenses rose $2.2M (+21%) driven by clinical/preclinical program advancement.